id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC12062019
core_pubmed_pmc
Therapeutic effects of medicinal and food-based traditional herbal couples on type 2 diabetes mellitus based on pharmacodynamics and pharmacokinetics
Therapeutic effects of medicinal and food-based traditional herbal couples on type 2 diabetes mellitus based on pharmacodynamics and pharmacokinetics Abstract Introduction Cinnamomi Ramulus (CR) is the dried bark of Cinnamomum cassia Presl, Lauraceae. Puerariae Lobatae Radix (PLR) is the dried root of the Pueraria loba...
PMC9240354
core_pubmed_pmc
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans Abstract The mitogen-activated protein kinase (MEK) inhibitor zapnometinib is in development to treat acute viral infections like COVID-19 and influenza. While the antiviral efficacy of zapnometini...
PMC10072151
core_pubmed_pmc
Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights Abstract Abstract Testosterone deficiency is diagnosed by a serum total testosterone level below 300 ng/dL in combination with symptoms such as decreased energy and libido. These symptoms can be am...
PMC5456383
core_pubmed_pmc
Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats
Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats Abstract Abstract Cats are the most common mammal to develop invasive fungal rhinosinusitis caused by cryptic species in Aspergillus section Fumigati that are resistant to azoles but susceptible to caspofungin. In this study nonlinear mixed-effects...
PMC6628605
core_pubmed_pmc
Factors related to lithium blood concentrations in Chinese Han patients with bipolar disorder
Factors related to lithium blood concentrations in Chinese Han patients with bipolar disorder Abstract Background: The goal of this study was to identify the physiological factors related to the blood concentration of lithium in Chinese Han patients with bipolar disorder (BD). Materials and methods: A total of 186 Chin...
PMC10940305
core_pubmed_pmc
Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression
Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression Abstract Abstract Huntington’s disease (HD) is an incurable inherited disorder caused by a repeated expansion of glutamines in the huntingtin gene ( Htt ). The mutant protein causes neuronal degeneration leading to seve...
PMC8742654
core_pubmed_pmc
Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial
Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial Abstract Abstract It remains uncertain whether pharmacokinetic changes following Roux‐en‐Y gastric bypass (RYGB) can be attributed to surgery‐induced gastro...
PMC12937387
core_pubmed_pmc
Unbound and Periprostatic Adipose Tissue Cefazolin Pharmacokinetics in Robotic-Assisted Radical Prostatectomy
Unbound and Periprostatic Adipose Tissue Cefazolin Pharmacokinetics in Robotic-Assisted Radical Prostatectomy Abstract Background/Objectives: This study aimed to describe the population pharmacokinetics of cefazolin (CFZ) using unbound serum and periprostatic adipose tissue concentrations and to optimize dosing regimen...
PMC12709979
core_pubmed_pmc
Targeted drug conjugates in cancer therapy: Challenges and opportunities
Targeted drug conjugates in cancer therapy: Challenges and opportunities Abstract Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies. Targeted drug conjugates (TDCs) typically comprise targeting ligands, such as speci...
PMC5577769
core_pubmed_pmc
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS Abstract Abstract Background Laquinimod is an oral immunomodulator in clinical development to treat relapsing-remitting multiple sclerosis (RRMS). Laquinimod is in clinical development for the treatment of multiple scleros...
PMC10747545
core_pubmed_pmc
A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients
A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients Abstract Abstract Introduction: Ondansetron is a drug that is routinely prescribed for the management of nausea and vomiting associated with cancer, radiation therapy, and surgical operations. It is m...
PMC4558989
core_pubmed_pmc
Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP)
Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP) Abstract Abstract Background Adverse effects of drugs are poorly reported in the literature . The aim of this study was ...
PMC10508503
core_pubmed_pmc
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma Abstract Abstract Tominersen is an intrathecally administered antisense oligonucleotide targeting huntingtin mRNA which leads to a dose‐dependent, reversible ...
PMC6191080
core_pubmed_pmc
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects Abstract Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection. Methods This three-...
PMC12256667
core_pubmed_pmc
Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model‐Informed Precision Dosing for Chinese Population With Renal Insufficiency
Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model‐Informed Precision Dosing for Chinese Population With Renal Insufficiency Abstract ABSTRACT Dose‐dependent hematological toxicity of lenalidomide has been reported previously, and thus, there is a clinical need for dose i...
PMC11873917
core_pubmed_pmc
The impact of pharmacist-led education and prospective audit and feedback on antibiotic dose optimization within medical intensive care units in Thailand: a retrospective study
The impact of pharmacist-led education and prospective audit and feedback on antibiotic dose optimization within medical intensive care units in Thailand: a retrospective study Abstract ABSTRACT Background Critical illness can affect antimicrobial pharmacokinetics and pharmacodynamics. Antimicrobial stewardship program...
PMC10580175
core_pubmed_pmc
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia Abstract Key Points • Pharmacodynamic exposures of HU used to treat patients with SCA directly kill malaria parasites at schizont stages. • A new biological model is presented for the global health treatments of major hem...
PMC8113206
core_pubmed_pmc
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis Abstract Abstract Background Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is we...
PMC6046493
core_pubmed_pmc
Futility of current urine salbutamol doping control
Futility of current urine salbutamol doping control Abstract Aims Salbutamol is used in the management of obstructive bronchospasm, including that of some elite athletes. It is claimed that high salbutamol (oral) doses may also have an anabolic effect. Therefore, inhalation of salbutamol is restricted by the World Anti...
PMC11286744
core_pubmed_pmc
Diffusion of nanoparticles in heterogeneous hydrogels as vitreous humour in vitro substitutes
Diffusion of nanoparticles in heterogeneous hydrogels as vitreous humour in vitro substitutes Abstract Nanomedicine has the potential to increase the biostability of drugs to treat retinal diseases, improving their performance and decreasing the required number of intravitreal injections. However, accurate pharmacokine...
PMC4086741
core_pubmed_pmc
Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach
Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach Abstract Nilotinib (Tasigna) is a tyrosine kinase inhibitor approved by the FDA to treat chronic phase chronic myeloid leukemia...
PMC6884875
core_pubmed_pmc
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial Abstract Abstract Background There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenou...
PMC10832411
core_pubmed_pmc
Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC
Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC Abstract Abstract Background: A statistical model is essential in determining the appropriate p...
PMC12638736
core_pubmed_pmc
Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity
Chronotherapy as a novel strategy to limit anthracycline-induced cardiotoxicity Abstract Abstract Anthracycline cardiotoxicity is a severe chemotherapeutic side effect that can lead to heart failure in cancer patients and survivors. Chronomodulated chemotherapy is a promising preventive strategy that encompasses the ad...
PMC2943398
core_pubmed_pmc
The warfarin–cranberry juice interaction revisited: A systematic in vitro–in vivo evaluation
The warfarin–cranberry juice interaction revisited: A systematic in vitro–in vivo evaluation Abstract Abstract Background Cranberry products have been implicated in several case reports to enhance the anticoagulant effect of warfarin. The mechanism could involve inhibition of the hepatic CYP2C9-mediated metabolic clear...
PMC8603594
core_pubmed_pmc
Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients
Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients Abstract Background It has been hypothesized that polypharmacy may increase the frequency of multidrug interactions (MDIs) where one drug interacts with two or more other drugs, amplifying the risk of associated ...
PMC4791487
core_pubmed_pmc
Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches
Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches Abstract Abstract Input estimation is employed in cases where it is desirable to recover the form of an input function which cannot be directly observed and for which there is no model for the generating process. In pharma...
PMC9192929
core_pubmed_pmc
A Review of Population Pharmacokinetic Analyses of Linezolid
A Review of Population Pharmacokinetic Analyses of Linezolid Abstract In recent years, many studies on population pharmacokinetics of linezolid have been conducted. This comprehensive review aimed to summarize population pharmacokinetic models of linezolid, by focusing on dosage optimization to maximize the probability...
PMC9571692
core_pubmed_pmc
New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects
New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects Abstract Abstract Pterostilbene (PTS), a compound most abundantly found in blueberries, is a natural analog of resveratrol. Several plant species, such as peanuts and grapes, produce PTS. While resveratrol has been extensively st...
PMC12267172
core_pubmed_pmc
Glutamine potentiates cefoperazone-sulbactam activity against Pseudomonas aeruginosa by increasing membrane permeability and cellular uptake
Glutamine potentiates cefoperazone-sulbactam activity against Pseudomonas aeruginosa by increasing membrane permeability and cellular uptake Abstract Abstract Purposes The combination of an antibiotic with a metabolic reprogramming agent is anticipated to emerge as a promising therapeutic strategy against antibiotic-re...
PMC4844258
core_pubmed_pmc
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan Abstract A low sodium diet enhances the hemodynamic effect of renin–angiotensin system blockers. It was suggested that the substrates of P-glycoprotein or cytochrome P450 3A4 were reduced on a high sodium diet. This study...
PMC7911663
core_pubmed_pmc
Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise Abstract Abstract Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than id...
PMC8537637
core_pubmed_pmc
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis Abstract Model-informed precision dosing (MIPD) may be a solution to therapeutic failure of infliximab for patients with ulcerative colitis (UC), as und...
PMC6625456
core_pubmed_pmc
Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual-acting cholinesterase inhibitor and histamine-3 receptor antagonist
Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual-acting cholinesterase inhibitor and histamine-3 receptor antagonist Abstract Abstract DL0410, a dual-action cholinesterase inhibitor and histamine-3 receptor antagonist with a novel structural scaffold, may be a potential candidate for the treatment...
PMC10375416
core_pubmed_pmc
EEG response of dexmedetomidine during drug induced sleep endoscopy
EEG response of dexmedetomidine during drug induced sleep endoscopy Abstract Abstract Introduction Dexmedetomidine is one of the anesthetics of choice for drug induced sleep endoscopy (DISE), with advantages including limited respiratory depression, analgesia, and decreased incidence of emergence delirium. However, cha...
PMC11870943
core_pubmed_pmc
A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron
A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron Abstract Abstract Iron is essential for every cell of the mammalian organism. Iron deficiency is a major public health issue worldwide. Intravenous (IV) iron therapy has been used to treat anemia. However, IV iron therapy is kno...
PMC11596214
core_pubmed_pmc
The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug–Drug Interactions
The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug–Drug Interactions Abstract Membrane transporters are expressed in a wide range of tissues in the human organism. These proteins regulate the penetration of various substances such as simple ions,...
PMC9570602
core_pubmed_pmc
The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer—Hyperthermia versus Normothermia: A Randomized Controlled Trial
The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer—Hyperthermia versus Normothermia: A Randomized Controlled Trial Abstract Abstract Background: The treatment of ovarian carcinomatosis with cytoreductive surgery and HIPEC is...
PMC3929454
core_pubmed_pmc
Methods for site-specific drug conjugation to antibodies
Methods for site-specific drug conjugation to antibodies Abstract Antibody drug conjugates (ADCs) are an emerging class of targeted therapeutics with the potential to improve therapeutic index over traditional chemotherapy. Drugs and linkers have been the current focus of ADC development, in addition to antibody and ta...
PMC5668067
core_pubmed_pmc
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET -amplified gastric cancer
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET -amplified gastric cancer Abstract SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escal...
PMC10508536
core_pubmed_pmc
Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models
Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models Abstract Abstract Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for treating chronic lymphocytic leukemia (CLL). It has also been associated...
PMC12424523
core_pubmed_pmc
Precision Daptomycin Dosing: Comparison of 3‐, 2‐, 1‐, and 0‐Concentration Sample Strategies
Precision Daptomycin Dosing: Comparison of 3‐, 2‐, 1‐, and 0‐Concentration Sample Strategies Abstract ABSTRACT Background Daptomycin is a once‐daily lipopeptide antibiotic with a narrow therapeutic window. As higher doses (8–12 mg/kg) are increasingly used to treat resistant gram‐positive infections, achieving therapeu...
PMC10118082
core_pubmed_pmc
Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5
Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5 Abstract This study sought to understand the nature of the immune complexes that could be formed when a patient is exposed simultaneously to two different anti-complement component...
PMC10487787
core_pubmed_pmc
Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients Abstract Resistance to anticancer agents is a major obstacle to efficacious tumour therapy and responsible for high cancer-related mortality rates. Some resistance mechanisms are associ...
PMC9575485
core_pubmed_pmc
Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever Abstract Abstract Background Children with febrile neutropenia commonly exhibit alterations of pharmacokinetic (PK) parameters, leading to decreased β‐lactam concentrations. Aims This study evaluate...
PMC6126716
core_pubmed_pmc
N-glycan microheterogeneity regulates interactions of plasma proteins
N-glycan microheterogeneity regulates interactions of plasma proteins Abstract Significance Glycosylation is one of the most common and complex posttranslation modifications that significantly influences protein structure and function. However, linking individual glycan structures to protein interactions remains challe...
PMC12298822
core_pubmed_pmc
Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study
Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study Abstract Abstract Sitagliptin is an orally bioavailable selective DPP4 inhibitor that reduces blood glucose levels without significant increases in ...
PMC9807765
core_pubmed_pmc
Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota Abstract Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbi...
PMC8620954
core_pubmed_pmc
PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice Abstract The importance of closely observing patients receiving antibiotic therapy, performing therapeutic drug monitoring (TDM), and regularly adjusting dosing regimens has been extensively demonstrat...
PMC8123513
core_pubmed_pmc
Hypoalbuminemia as Surrogate and Culprit of Infections
Hypoalbuminemia as Surrogate and Culprit of Infections Abstract Hypoalbuminemia is associated with the acquisition and severity of infectious diseases, and intact innate and adaptive immune responses depend on albumin. Albumin oxidation and breakdown affect interactions with bioactive lipid mediators that play importan...
PMC6921036
core_pubmed_pmc
Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using in Silico Tools
Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using in Silico Tools Abstract Gemcitabine is an anticancer drug used to treat a wide range of solid tumors and is a first line treatment for pancreatic cancer. Our group has previously developed novel conjugates of gemcitabine with c...
PMC11112918
core_pubmed_pmc
Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review
Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review Abstract Abstract Background The proportion of patients with breast cancer and obesity is increasing. While the therapeutic landscape of breast cancer has been expanding, we lack knowledge about t...
PMC12507935
core_pubmed_pmc
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results Abstract Purpose OX40 may stimulate T-cell activation, potentially enhanced with checkpointinhibition. Results are from the dose-escalation part of...
PMC11661808
core_pubmed_pmc
Pharmacokinetics and metabolism of ketoconazole after single ocular instillation in Sprague-Dawley rats
Pharmacokinetics and metabolism of ketoconazole after single ocular instillation in Sprague-Dawley rats Abstract Abstract Background and purpose Ketoconazole is limited to its conditioned oral use due to hepatic toxicity. Its ocular eye drop administration may be an option for mycotic keratitis treatment. Therefore, it...
PMC3996097
core_pubmed_pmc
Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report
Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report Abstract Abstract Introduction Many antiepileptic drugs decrease the efficacy of combined hormonal contraceptives due to their inducing effect on cytochrome P450 liver metabolism. Less is known about the pharmacokinetic...
PMC11750939
core_pubmed_pmc
A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer
A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer Abstract Abstract Purpose The primary objectives of this trial were aimed at exploring the pharmacokinetic profiles and the human bioe...
PMC6824359
core_pubmed_pmc
Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD
Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD Abstract Introduction During the clinical development of a fixed-dose combination of drugs, it is best practice to conduct dose-finding studies to determine the ...
PMC6021360
core_pubmed_pmc
Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers Abstract Background Carvedilol is commonly used to treat hypertension as a β- and α 1 -adrenoreceptor blocker, but it is metabolized by CYP2D6, and CYP2D6 * 10 allele is dominant in Asian p...
PMC10609929
core_pubmed_pmc
Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin Abstract Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an ...
PMC3863463
core_pubmed_pmc
Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It?
Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It? Abstract Abstract Oral anticoagulant (OAC) therapy in haemodialysis patients causes a great deal of controversy. This is because a number of pro- and anticoagulant factors play an important role in end-stage renal failure due to t...
PMC6149971
core_pubmed_pmc
In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti- P. falciparum and Anti- P. vivax Blood-Stage Antimalarial
In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti- P. falciparum and Anti- P. vivax Blood-Stage Antimalarial Abstract Abstract Natural products are a prolific source for the identification of new biologically active compounds. In the present work, we studie...
PMC5432557
core_pubmed_pmc
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia Abstract Opinion Statement Schizophrenia is a mostly chronic mental disorder, and symptomatic relapse is frequently observed. It is often associated with social and/or occupational decline that can be difficult to reverse. Most patients with the illness ...
PMC5980437
core_pubmed_pmc
Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab Abstract Summary We examined the assay formats used to detect anti‐drug antibodies (ADA) in clinical studies of the anti‐tumour necrosis factor (TNF) monoclonal antibodies adalimumab and infliximab in chr...
PMC10823771
core_pubmed_pmc
Investigating the replacement of carboxylates with carboxamides to modulate the safety and efficacy of platinum(II) thioether cyanide scavengers
Investigating the replacement of carboxylates with carboxamides to modulate the safety and efficacy of platinum(II) thioether cyanide scavengers Abstract Abstract Cyanide represents a persistent threat for accidental or malicious misuse due to easy conversion into a toxic gas and access to large quantities through seve...
PMC7543973
core_pubmed_pmc
Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools
Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools Abstract Abstract Chloroquine (CQ) and hydroxychloroquine (HCQ) are undergoing several clinical trials for evaluating their efficacy and safety as antiviral drugs. Yet, t...
PMC6955414
core_pubmed_pmc
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study Abstract Abstract Aims Type 2 diabetes mellitus (T2DM) is commonly complicated by renal impairment. Polyethylene glycol loxenatide (PEX168) is a novel long‐acting glucagon‐like peptide‐1 receptor agonist for T2DM. PEX168 ...
PMC8521398
core_pubmed_pmc
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia Abstract Abstract Objectives Lung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed ...
PMC12573052
core_pubmed_pmc
Fe 3 O 4 –Chitosan Nanocomposite as a pH-Responsive Delivery System for Enhanced Delivery of Punica Granatum L. Polyphenols
Fe 3 O 4 –Chitosan Nanocomposite as a pH-Responsive Delivery System for Enhanced Delivery of Punica Granatum L. Polyphenols Abstract Abstract Punica granatum extract (PG), consisting of punicalagin, ellagic acid, and gallic acid, was loaded onto an Fe 3 O 4 /Chitosan (Fe 3 O 4 @Chi) nanocomposite (Fe 3 O 4 @Chi-PG) to ...
PMC10687595
core_pubmed_pmc
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia Abstract Abstract Optimal antituberculosis therapy is essential for favorable clinical outcomes. Peak plasma concentrations of first-line antituberculosis drugs in infants with living HIV receivin...
PMC6274433
core_pubmed_pmc
Bioanalytical Method Development Using Liquid Chromatography with Amperometric Detection for the Pharmacokinetic Evaluation of Forsythiaside in Rats
Bioanalytical Method Development Using Liquid Chromatography with Amperometric Detection for the Pharmacokinetic Evaluation of Forsythiaside in Rats Abstract Abstract An analytical method entailing high-performance liquid chromatography coupled with electrochemical detection was developed for determining forsythiaside ...
PMC12641797
core_pubmed_pmc
Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide
Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide Abstract Abstract Extracorporeal membrane oxygenation (ECMO) is increasingly used to support critically ill adults with severe cardiac or respiratory failure, but ECMO circuits and the physiological disturbances of cr...
PMC4997882
core_pubmed_pmc
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi Abstract Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifung...
PMC3362727
core_pubmed_pmc
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men Abstract Abstract Purpose To evaluate pharmacokinetics, safety, and tolerability of abiraterone acetate (AA) in healthy men. Methods Two phase I studies (dose-escalation study and dose-proportionality study) were conducted in healthy men...
PMC10304326
core_pubmed_pmc
Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults
Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults Abstract Abstract Background The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and subsequent Coronavirus Disease 2019 (COVID-19) pandemic ha...
PMC11279310
core_pubmed_pmc
Liver-on-chips for drug discovery and development
Liver-on-chips for drug discovery and development Abstract Recent FDA modernization act 2.0 has led to increasing industrial R&D investment in advanced in vitro 3D models such as organoids, spheroids, organ-on-chips, 3D bioprinting, and in silico approaches. Liver-related advanced in vitro models remain the prime area ...
PMC12620837
core_pubmed_pmc
Structure-Guided Discovery of Drug-like Compounds Targeting HPV16 E6 for Antiviral Therapy Development
Structure-Guided Discovery of Drug-like Compounds Targeting HPV16 E6 for Antiviral Therapy Development Abstract Background: Human papillomavirus type 16 (HPV16) E6 oncoprotein is a key factor in the progression of cervical and other HPV-related cancers. Targeting E6 with small molecule inhibitors represents a promising...
PMC11359928
core_pubmed_pmc
Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature
Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature Abstract Abstract 3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative with notable psychoactive properties and emerging therapeutic potential, particularly for treating post-traumatic stress dis...
PMC4068832
core_pubmed_pmc
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia Abstract Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with 5-year disease-free survival (DFS) ranging from under 10% to over 70% for distinct groups of patients. At our institution, cytara...
PMC11752114
core_pubmed_pmc
Unlocking the potential of luteolin: A natural migraine management approach through network pharmacology
Unlocking the potential of luteolin: A natural migraine management approach through network pharmacology Abstract Background Luteolin, a natural flavonoid, exhibits antioxidant and anti-inflammatory properties and has been investigated for potential health benefits. Its focus on migraine management arises from its abil...
PMC12546168
core_pubmed_pmc
Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach
Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach Abstract Background Breast cancer is one of the most common cancer types among women, especially in developing and underdeveloped nations like Nigeria. Anexelekto (AXL) ...
PMC8604249
core_pubmed_pmc
Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study
Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study Abstract Abstract The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separa...
PMC6207247
core_pubmed_pmc
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects Abstract Purpose This double-blind, placebo-controlled, intra-subject, dose-escalation study assessed single-dose safety, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese and ...
PMC6272426
core_pubmed_pmc
LC-ESI-MS/MS Analysis and Pharmacokinetics of GP205, an Innovative Potent Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease in Rats
LC-ESI-MS/MS Analysis and Pharmacokinetics of GP205, an Innovative Potent Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease in Rats Abstract A high-throughput, sensitive and specific LC-ESI-MS/MS method was established for the quantitative determination of GP205, a potent inhibitor of hepatitis C virus NS3/4A ...
PMC3596677
core_pubmed_pmc
Single-dose and multiple-dose pharmacokinetics of zaltoprofen after oral administration in healthy Chinese volunteers
Single-dose and multiple-dose pharmacokinetics of zaltoprofen after oral administration in healthy Chinese volunteers Abstract Abstract Zaltoprofen, a propionic acid derivative of non-steroidal anti-inflammatory drugs, has strong inhibitory effects on actue and chronic inflammation. A randomized, dose-escalating study ...
PMC5983471
core_pubmed_pmc
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer Abstract Background Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading cons...
PMC11723924
core_pubmed_pmc
GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura
GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by the formation of blood clots in small blood vessels. It is caused by antibodie...
PMC10106327
core_pubmed_pmc
Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations
Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations Abstract Abstract Invasive mold diseases are devastating systemic infections which demand meticulous care in selection, dosing, and therapy monitoring of antifungal drugs. Various circumstances regarding...
PMC8413870
core_pubmed_pmc
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A Abstract Abstract Introduction Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94–9027, Jivi, Baye...
PMC9377374
core_pubmed_pmc
Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia Abstract Cyclosporine (CsA) is a component of the first-line treatment for acquired aplastic anemia (acquired AA) in pediatric patients. This study aimed to develop a population pharmacokinetic (PK) model of CsA in C...
PMC8472738
core_pubmed_pmc
Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities
Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities Abstract Abstract HM-3, an integrin antagonist, exhibits anti-tumor biological responses and therefore has potential as a therapeutic polypeptide. However, the clinical applications of HM-3 are limited by its sho...
PMC10124690
core_pubmed_pmc
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India Abstract Purpose Very few studies have demonstrated the rituximab biosimilarity in terms of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity in patients with diffuse large B-cell lymphoma...
PMC11286753
core_pubmed_pmc
Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis
Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis Abstract Bacterial vaginosis (BV), primarily attributed to Gardnerella vaginalis , poses significant challenges due to antibiotic resistance and suboptimal treatment outcomes. This...
PMC9510632
core_pubmed_pmc
Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients
Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients Abstract Abstract Paroxetine is one of the most potent selective serotonin reuptake inhibitors (SSRIs) approved for treating depressi...
PMC7934007
core_pubmed_pmc
New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage
New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage Abstract Abstract Chronic hepatitis B virus (HBV) infection (CHB) is a public health concern worldwide. Current therapies utilizing nucleos(t)ide analogs (NA) have not resulted in ...
PMC8027707
core_pubmed_pmc
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review Abstract Abstract People living with HIV should be considered candidates for solid-organ transplantation (SOT). However, managing HIV-infected patients...
PMC9237521
core_pubmed_pmc
UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma Abstract Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib h...
PMC10606375
core_pubmed_pmc
A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling
A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling Abstract Abstract The administration of therapeutic drugs through dermal routes, such as creams and ointments, has emerged as an increasingly popular alternative to traditional delivery methods, such as t...
PMC7323267
core_pubmed_pmc
Evaluation of the Efficacy and Safety of the Herbal Formula PM014 in a Cisplatin- and Paclitaxel-Treated Tumor-Bearing Mouse Model
Evaluation of the Efficacy and Safety of the Herbal Formula PM014 in a Cisplatin- and Paclitaxel-Treated Tumor-Bearing Mouse Model Abstract PM014 (HL301) is a standardized herbal mixture derived from a traditional Korean medicine, Chung-Sang-Bo-Ha-Tang. Previously, we reported that PM014 treatment significantly suppres...
PMC7359932
core_pubmed_pmc
Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin Abstract Abstract The pharmacokinetic (PK) properties of drugs are affected in several ways by interactions with microbiota. The aim of this study was to investigate the effects of oral vancomycin on the gut microbi...
PMC5410349
core_pubmed_pmc
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors Abstract Abstract Purpose To determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan...